Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Co. focuses on the field of ophthalmology, where it has clinical programs in X-linked retinitis pigmentosa and achromatopsia. Co. also has clinical-stage program in optogenetics, and pre-clinical programs in central nervous system, and several other ophthalmology, and otology indications. Co. has developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology. The AGTC stock yearly return is shown above.
The yearly return on the AGTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|